Auris Medical Holding AG (NASDAQ:EARS)’s share price was down 18.2% during trading on Monday . The stock traded as low as $0.35 and last traded at $0.36. Approximately 4,817,269 shares traded hands during mid-day trading, an increase of 161% from the average daily volume of 1,844,024 shares. The stock had previously closed at $0.44.
A number of equities analysts have recently issued reports on EARS shares. Roth Capital started coverage on Auris Medical in a research report on Thursday, December 20th. They set a “buy” rating and a $5.00 price target on the stock. ValuEngine raised Auris Medical from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st. Finally, Zacks Investment Research downgraded Auris Medical from a “buy” rating to a “hold” rating in a research report on Monday, January 21st.
The stock has a market capitalization of $14.74 million, a PE ratio of -0.06 and a beta of -0.57.
About Auris Medical (NASDAQ:EARS)
Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its product candidates include AM-101, which is in phase III clinical development for the treatment of acute inner ear tinnitus; and AM-111 that is in phase III clinical development for the treatment of acute inner ear hearing loss.
Further Reading: Price-Sales Ratio
Receive News & Ratings for Auris Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical and related companies with MarketBeat.com's FREE daily email newsletter.